RE: 2021 will be a huge year for Avacta!29 Dec 2020 16:06
Infinis, I’d say if the AVA6000 proves to deliver the chemo to the FAP in all 12 patients, without the en route side effects, it will be job done there and then as far as the SP goes. Hard to say what it might be but sure it can be extrapolated as a percentage proportion of most of the chemos in the world market, which would be vast because a proper multiple could be applied to its annual sales. In time it would surely render Doxorubicin and others useless without the AVA6000.
It would also be an historic medical achievement.
Presumably we’d get updates on the application feedback in Feb/March to get a clear timing on the first patient dosing.